{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:59:18Z","timestamp":1790949558012,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K19239"],"award-info":[{"award-number":["24K19239"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Our aim was to explore maintenance of glucocorticoid\u2010free remission in patients with idiopathic inflammatory myopathy (IIM). Additionally, we examined the performance of the International Myositis Assessment and Clinical Study Group (IMACS) criteria for complete clinical response and flare\/worsening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients achieving physician\u2010determined glucocorticoid\u2010free remission were extracted from the Swedish Rheumatology Quality Register (SRQ). Relapse rates and associated factors were analyzed. To assess the performance of complete clinical response criteria, IMACS core set measures were evaluated within six months before and after remission. Relapse was defined as IMACS criteria of worsening in IMACS core set measures over 20% to 30% during every visit or in the period from remission to a time point with worsening (modified definition) or glucocorticoid\/immunosuppressant administration. Changes from remission to all subsequent visits were compared. The visit with the largest change was chosen as the worse time point (modified definition).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 494 patients, 159 (32%) achieved physician\u2010determined glucocorticoid\u2010free remission. The 12\u2010year cumulative relapse rate was 76%, with anti\u2010Jo1 as a risk factor. From time of remission to six months after remission, IMACS complete clinical response fulfillment rates were as follows: creatine kinase, 23%; Health Assessment Questionnaire, 50%; patient global assessment, 70%; physician global assessment, 80%; extramuscular activity, 83%; and Manual Muscle Test 8, 95%. Only 50% of relapses could be captured by the IMACS worsening definition, but additional relapses were captured by a modified IMACS worsening definition (15%) or by reintroduction of glucocorticoid\/immunosuppressant treatment (35%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Relapses were frequent in patients with IIM after achieving glucocorticoid\u2010free remission and required management of therapy. IMACS criteria for complete clinical response\/worsening need to be amended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.43429","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T10:57:16Z","timestamp":1762772236000},"page":"936-947","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Relapse Rate After Glucocorticoid\u2010Free Remission in Patients With Idiopathic Inflammatory Myopathies and Validation of the International Myositis Assessment and Clinical Studies Group Criteria for Complete Clinical Response and Worsening"],"prefix":"10.1002","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2521-246X","authenticated-orcid":false,"given":"Hideaki","family":"Tsuji","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine Kyoto University  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6227-8209","authenticated-orcid":false,"given":"Fabricio","family":"Espinosa\u2010Ortega","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Gastroenterology, Dermatology, Rheumatology, Theme Inflammation and Aging Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Peralta Garcia","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Gastroenterology, Dermatology, Rheumatology, Theme Inflammation and Aging Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Dastmalchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Gastroenterology, Dermatology, Rheumatology, Theme Inflammation and Aging Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9212","authenticated-orcid":false,"given":"Ingrid E.","family":"Lundberg","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Gastroenterology, Dermatology, Rheumatology, Theme Inflammation and Aging Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lodin","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Gastroenterology, Dermatology, Rheumatology, Theme Inflammation and Aging Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"10","key":"e_1_2_7_2_1","first-page":"2230","article-title":"Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis","volume":"28","author":"Marie I","year":"2001","journal-title":"J Rheumatol"},{"issue":"3","key":"e_1_2_7_3_1","first-page":"213","article-title":"Polymyositis\u2010dermatomyositis:25 years of follow\u2010up of 50 patients disease course, treatment, prognostic factors","volume":"22","author":"Chwali\u0144ska\u2010Sadowska H","year":"1990","journal-title":"Mater Med Pol"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00321-x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7313-z"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.15570\/actaapa.2020.5"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199812)21:12<1668:AID-MUS7>3.0.CO;2-#"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21291"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.33"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key450"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40320"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0180"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.03.001"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.09.016"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20532"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010111"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000066"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2016-000157"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5447-25"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216303"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh297"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30129"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"issue":"1","key":"e_1_2_7_25_1","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"Vollenhoven RF","year":"2021","journal-title":"Lupus Sci Med."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13317-014-0063-1"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916930600622884"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1317377"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-0075-3"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-1736"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12444"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e31829d08f9"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.10.010"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42450"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43429","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.43429","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:16:42Z","timestamp":1775546202000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.43429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/art.43429"],"URL":"https:\/\/doi.org\/10.1002\/art.43429","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"2025-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}